The Effect of SKY Breath Meditation on Health and Well-being

February 26, 2026 updated by: Ritu Aneja, University of Alabama at Birmingham

A Pilot Feasibility Study to Evaluate the Effect of SKY Breath Meditation on Health and Well-being

The goal of this pilot SKY (Sudarshan Kriya Yoga) Breath Meditation study is to establish feasibility and acceptability of the intervention; and investigate preliminary effectiveness of the intervention at the DNA methylation, RNA and protein levels in blood samples collected from participants before and after the 8 week SKY intervention. Primary outcomes also include preliminary effectiveness at the physiological level using a wearable device used for continuous monitoring. Secondary outcome measures include behavioral inventories.

Study Overview

Detailed Description

The present study will recruit up to 60 participants in the SKY intervention and up to 60 participants in the control group. Recruitment is expected to take up to a year. After providing informed consent, participants will be randomly assigned to the SKY intervention group, or a waitlist control group. Interventions will be performed in-person in San Diego.

Prior to interventions, each participant will be asked to fill out behavioral questionnaires containing surveys and standardized cognitive measurements. Participants will be also asked to provide blood samples for biological assays (epigenetics, transcriptomics and proteomics). All participants will be scheduled for the questionnaire data collection and specimen collection up to two weeks preceding the start of either intervention. Participants will be asked to wear a Garmin vivoSmart5 smartwatch to collect physiological measures.

The SKY intervention will be administered in-person over three sessions over three consecutive days. All participants (SKY and control) will be asked to provide a second blood sample at the end of the third session of the SKY intervention. SKY participants will then engage in a remotely administered follow-up over up to eight weeks' time with the option to attend daily remotely-led breathwork sessions for 30 minutes. Participants will be asked to log daily practice engagement using online surveys through the eight-week follow-up period. Reminders will be provided to the participant intermittently during this time. During the period of eight weeks, the participants will return for 1-hour in-person follow-up SKY sessions once a week. They will be required to attend at least 75% of these weekly sessions. After 8 weeks of follow up, participants will provide a third sample of blood, and perform a post-intervention questionnaire.

Control participants will also have a similar schedule of data and biological sample collection as the SKY group. Waitlist controls will be provided the opportunity to attend the SKY retreat free of charge at the conclusion of the follow up period.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Diego, California, United States, 92129
        • Study Site: Confidential

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 50 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy volunteers over 21 years of age who are willing to meet the standards of the study.
  • Minimum 5th grade equivalent competency in English
  • Agree to complete all follow up sessions per week of SKY Breath practice.

Exclusion Criteria:

  • Diagnosis of any major medical condition including, but not limited to: dementia, severe hypertension, cancer, diabetes, rheumatoid arthritis, asthma or respiratory illnesses, history of seizure disorder, Crohn's disease, lupus, colitis, dermatitis, fibromyalgia, HIV, hepatitis B or C.
  • Diagnosis of any psychiatric condition including, but not limited to: severe clinical depression, bipolar disorder, schizophrenia/schizoaffective disorder, suicidal ideation, ADHD
  • Recent history of major psychotic episode within the last 12 months
  • Recent history of consistent substance dependence or abuse either by history or self-report within the last 3 months
  • Major surgery within last 12 weeks
  • On hormone-replacement therapy
  • Taking lithium or lithium-based medication
  • Currently pregnant/breastfeeding or actively trying to become pregnant
  • BMI greater than 35
  • Exhibiting symptoms like prolonged cognitive fog or difficulty breathing.
  • Smokes any tobacco products (including cigarettes, vapes, hookah)
  • Heavy alcohol drinker (per CDC definition, 8 or more drinks per week for women, 15 or more drinks per week for men)
  • Concurrently participating in another pilot study/clinical trial of a mind/body intervention
  • Regularly practices (3+ times a week) a formal meditation or breath-based technique

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Waitlist control participants will not be provided any intervention. However, they will have the same schedule for data and biological specimen collection as the SKY intervention participants. They will be provided an opportunity to take the SKY retreat free of charge at the end of the follow up period.
Experimental: SKY
In-person SKY sessions will be 3 hours long on each of 3 consecutive days, and participants must be willing to attend all 3 sessions. Each session comprises a combination of breathwork, emotional resilience training, yoga, and leadership skills. The SKY technique includes a unique set of standardized breathing techniques to rapidly reduce neuroendocrine stress responses and the autonomic imbalance due to sympathetic overdrive. 8 weeks of online and/or in-person sessions will be delivered to participants in the follow-up period after the initial in-person intervention. They will receive intermittent reminders about their daily practice during the 8-week follow-up period. The participants will be asked to engage in daily 30 minute SKY sessions remotely, that is led by an instructor. Each participant will be required to log in the number of times a week they practice. In addition, weekly 60-minute reinforcement sessions will be conducted, in-person.
The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 35 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive intermittent reminders about their daily practice during the 8-week follow-up period.
Other Names:
  • Sudarshan Kriya Yoga
  • SKY Breath Meditation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recruitment rate
Time Frame: Up to 1 year
Descriptive statistics will be used to compute the proportion of screen-eligible participants enrolled by consent. Proportions will be computed, along with 95% confidence intervals, to indicate the precision of the point estimate.
Up to 1 year
Refusal rate
Time Frame: Up to 1 year
Descriptive statistics will be used to compute the proportion of screen-eligible individuals who refused to participate. Proportions will be computed, along with 95% confidence intervals, to indicate the precision of the point estimate.
Up to 1 year
Retention rate
Time Frame: Week to week during 8 weeks
Among the participants who originally attended the 3-day workshop, descriptive statistics will be used to compute proportion of participants that complete all 8 SKY follow-up study visits. Proportions will be computed, along with 95% confidence intervals, to indicate the precision of the point estimate.
Week to week during 8 weeks
Adherence rate
Time Frame: 8 weeks during intervention period
Descriptive statistics will be used to compute the frequency of home practice completion, weekly, by the intervention participants. Proportions will be computed, along with 95% confidence intervals, to indicate the precision of the point estimate.
8 weeks during intervention period
Heart rate variability
Time Frame: Continuous monitoring over 8-week intervention
Heart rate variability will be collected using the Garmin vivosmart5 watch
Continuous monitoring over 8-week intervention
Respiration rate
Time Frame: Continuous monitoring over 8-week intervention
Respiration rate will be measured using the Garmin vivosmart5 watch
Continuous monitoring over 8-week intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perceived Stress Scale
Time Frame: Pre/post 8-week intervention
The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Lower values indicate less stress.
Pre/post 8-week intervention
Brief-COPE
Time Frame: Pre/post 8-week intervention
The Brief-COPE is a 28 item self-report questionnaire designed to measure effective and ineffective ways to cope with a stressful life event. Higher scores indicate difficulty with coping.
Pre/post 8-week intervention
Pittsburgh Sleep Quality Assessment
Time Frame: Pre/post 8-week intervention
The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month. Higher scores indicate more sleep disturbances.
Pre/post 8-week intervention
Mini-Mood and Anxiety Symptom Questionnaire
Time Frame: Pre/post 8-week intervention
The Mood and Anxiety Symptom Questionnaire (MASQ) is an instrument containing a range of symptoms relevant to depression and anxiety. Items are evaluated for Distress, Anxiety, Depression with higher scores on subcomponents indicate more extreme levels of each metric.
Pre/post 8-week intervention
SF-12v2
Time Frame: Pre/post 8-week intervention
The SF-12v2 is a health-related quality-of-life questionnaire consisting of twelve questions that measure eight health domains to assess physical and mental health. Higher scores indicate better physical and mental health.
Pre/post 8-week intervention
Social-Connectedness Scale
Time Frame: Pre/post 8-week intervention
The social connectedness scale assesses the degree to which persons feel connected to others in their social environment. Higher scores indicate more social connectedness. The Social Connectedness Scale Revised [SCS-R; Cronbach's Alpha=0.94] will be used to measure social connectedness.
Pre/post 8-week intervention
Epigenetic (DNA Methylation) changes
Time Frame: Pre/post 8 week intervention, and Day 3 (midpoint)
DNA Methylation changes in SKY and control groups (pre vs post interventions) will be measured by EPIC v2 array and whole-genome bisulfite sequencing (WGBS). Data analyses will be performed utilizing previously published standard pipelines.
Pre/post 8 week intervention, and Day 3 (midpoint)
Gene expression changes
Time Frame: Pre/post 8 week intervention, and Day 3 (midpoint)
RNA level changes between SKY and control groups will be examined.
Pre/post 8 week intervention, and Day 3 (midpoint)
Proteomic changes
Time Frame: Pre/post 8 week intervention
Protein level changes between SKY and control groups will be examined.
Pre/post 8 week intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of changes in mitochondrial DNA damage-associated molecular patterns (mtDNA DAMPs) from blood serum.
Time Frame: Pre/post 8-week intervention
Cell-free DNA will be eluted to a specified serum volume and used for the mtDNA DAMPs assays.
Pre/post 8-week intervention
Cytokine changes in serum samples
Time Frame: Pre/post 8-week intervention
Cytokine changes will be measured using ELISA assay on the blood sample collected and a standard ELISA panel for pro-inflammatory cytokines will be used to detect changes in their levels post intervention.
Pre/post 8-week intervention
Serum biomarkers
Time Frame: Pre/post 8-week intervention
Serum samples will be collected using standard procedures from the blood samples and immunoassayed using enzyme-linked immunosorbent assay to detect serum biomarkers
Pre/post 8-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2023

Primary Completion (Actual)

April 19, 2024

Study Completion (Actual)

September 12, 2024

Study Registration Dates

First Submitted

August 19, 2022

First Submitted That Met QC Criteria

August 29, 2022

First Posted (Actual)

August 31, 2022

Study Record Updates

Last Update Posted (Actual)

March 2, 2026

Last Update Submitted That Met QC Criteria

February 26, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe